Raphy Gonzalez
General Practice · Hatillo, PRNPI 1972534501
Payments from drug & device makers
Across 180 payments — averaging $30.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Merck$1K
- Boehringer Ingelheim$888
- Eli Lilly Export S.A. Puerto Rico Branch$472
- Sanofi-aventis U.S. LLC$377
- Lilly USA, LLC$100
- plus $186 from 5 others
What the payments were for
- Consulting fees$95017%
- Food & beverage$4,50782%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 83 | $2,353 |
| Merck | 8 | $1,088 |
| Boehringer Ingelheim | 38 | $888 |
| Eli Lilly Export S.A. Puerto Rico Branch | 24 | $472 |
| Sanofi-aventis U.S. LLC | 17 | $377 |
| Lilly USA, LLC | 2 | $100 |
| Abbott | 3 | $71 |
| Dexcom, Inc. | 2 | $45 |
| PBG Puerto Rico LLC | 1 | $25 |
| Johnson & Johnson | 1 | $25 |
| Pfizer Pharmaceuticals LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,463 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xigduo XrDapaglifloz Propaned/Metformin | 44 | $27,018 |
| FarxigaDapagliflozin Propanediol | 16 | $9,434 |
| JentaduetoLinagliptin/Metformin Hcl | 15 | $7,970 |
| SynthroidLevothyroxine Sodium | 76 | $4,363 |
| Humalog Mix 75-25Insulin Lispro Protamin/Lispro | 13 | $2,313 |
| LantusInsulin Glargine,hum.Rec.Anlog | 17 | $1,383 |
| Atorvastatin Calcium | 217 | $1,305 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,297 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $1,285 |
| Gabapentin | 138 | $1,235 |
| Etodolac | 80 | $1,193 |
| Losartan Potassium | 112 | $808 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 18 | $570 |
| Metformin Hcl | 104 | $563 |
| Diltiazem 24hr ErDiltiazem Hcl | 11 | $517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $2,353 | $9,43416 claims |
| Boehringer IngelheimJentadueto | $888 | $7,97015 claims |
| Lilly USA, LLCHumalog Mix 75-25 | $100 | $2,31313 claims |
| Sanofi-aventis U.S. LLCLantus | $377 | $1,38317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Other general practice in Hatillo
- Gregorio Cortes-MaisonetSan Juan$12.8M
- Barbara Orozco PerezCanovanas$5.1M
- Jesus Rodriguez RodriguezPonce$4.9M
- Luis PaganDorado$3.3M
- Cindy MartinezHormigueros$3.2M
- Gustavo AlbizuMorovis$3.1M
- Elham GhorbaniDorado$1.2M
- Victor MorenoMaunabo$903K
- Grisselle Ortiz RiveraMorovis$715K
- Elba PerezTrujillo Alto$651K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.